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In summary, 16.4% of patients (group 1+3) were formally not treatable using TAVI.
Conclusion: The majority of patients with AVS scheduled for TAVI show suitable
AAS for current devices. Anyhow, a substantial number of patients are not eligible due
to oversized aortic annulus diameters. Consecutively, the development of larger
prostheses is crucial to embrace this not negligible minority of patients.
TCT-761
Prognostic Impact of Permanent Pacemaker Implantation Among Patients
With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve
Implantation
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Pilgrim1, Bernhard Meier1, Ulrich Gerckens2, Eberhard Grube3, Stephan Windecker1
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Background: The occurrence of conduction abnormalities requiring the implantation
of a permanent pacemaker (PPM) in patients undergoing transcatheter aortic valve
implantation (TAVI) is not rare, with an incidence ranging between 5-30% in published
series. To investigate the impact of PPM on prognosis, we compared clinical outcomes
of patients with severe aortic valve stenosis undergoing TAVI in the following three
groups: (1) patients with PPM prior to TAVI, (2) patients with TAVI-related PPM and
(3) patients without PPM before and after TAVI.
Methods: A total of 351 consecutive patients (mean age 82.1±6.7 years, mean
logEuroscore 24.2±15.4%) with symptomatic aortic valve stenosis (mean gradient
44.6±16.3mmHg) undergoing TAVI with use of the 18F Medtronic CoreValve
prosthesis (n=293, 83.5%; transfemoral: 288, subclavian: 5) or the Edwards Sapien
prosthesis (n=58, 16.5%, transfemoral: 24, transapical: 34) were prospectively followed
in this two-center observational study. A total of 47 patients (13.4%) had a PPM prior
to TAVI (group 1), 98 patients (27.9%) received a PPM during the peri-procedural
period (group 2) and 206 patients required no PPM during follow-up (group 3). The
primary endpoint of the study was mortality at one year follow-up. Secondary
endpoints included in-hospital mortality as well as rates of stroke and myocardial
infarction in-hospital and at one year.
Results: Device success was 97.4% without differences between the three groups. In-
hospital and one-year follow-up was available in 100% of alive patients. Overall
in-hospital and one year mortality were 4.6% (16/351) and 22.8% (80/351),
respectively, without significant differences among the different study groups (see
table). Rates of in-hospital stroke, infarction and access site complication were 2.6%,
0.9%, 13.7%. Detailed clinical follow-up will be presented.
Conclusion: In this observational study, patients with severe aortic stenosis undergoing
TAVI had a similar survival independent of the need of PPM implantation, which
underlines the benign nature of this complication.
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Predictive Factors and Prognostic Value of Periprocedural Myocardial Injury
During Transcatheter Aortic Valve Implantation
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Bouma, José P Henriques, Riccardo Cocchieri, Jan J Piek, Bas A de Mol, Jan Baan
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Background: Periprocedural myocardial injury (PMI) is a common complication
during cardiac surgery and percutaneous coronary intervention and is an important
predictor for postprocedural cardiovascular morbidity and mortality. Very few data
have been reported about the occurrence of myocardial damage associated with
transcatheter aortic valve implantation (TAVI). Therefore, our purpose was to
investigate the incidence, the predictive factors and clinical consequences of PMI
during TAVI.
Methods: In a prospective observational single-centre study, we included 117 patients
(age 81±8 years, 46 male), who had undergone a TAVI with the Medtronic-CoreValve®
bioprosthesis. Serum CK-MB and cTnT levels were measured pre- and
postprocedurally. Periprocedural myocardial injury was defined as a postprocedural
increase of CK-MB and/or cTnT level above 5 times the upper reference limit, as
obtained from the Valve Academic Research Consortium.
Results: Following TAVI the incidence of PMI was 18%. Independent predictive
factors for PMI were procedural duration (minutes, OR: 1.04; 95%CI: 1.01-1.07),
preprocedural beta-blocker use (OR: 0.13; 95%CI: 0.03-0.51), peripheral arterial
disease (OR: 6.08; 95%CI: 1.47-25.13) and prosthesis depth (millimeters, OR: 1.28;
95%CI: 1.05-1.56). Mortality within 30 days following TAVI was 13%. Predictive
factors identified for 30-day mortality were PMI (OR: 10.89; 95%CI: 2.49-47.53),
preprocedural hospitalization (OR: 9.96; 95%CI: 2.32-42.66) and left ventricular mass
index (gr/m2, OR: 1.02; 95%CI: 1.00-1.03).
Conclusion: Following transcatheter aortic valve implantation, serum levels of both
CK-MB and cTnT increase, which reflects the occurrence of periprocedural myocardial
injury. A longer procedural duration, the absence of beta-blocker use, peripheral arterial
disease and a deeper prosthesis insertion are associated with PMI. Together with
preprocedural hospitalization and left ventricular mass, PMI
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Aortic valve calcium scoring (AVCS) is a predictor of significant paravalvular
aortic insufficiency in transapical aortic valve implantation
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Background: Transapical aortic valve implantation (TA-AVI) has evolved as a routine
for selected high-risk patients. However, paravalvular leaks >1+ remain an unsolved
issue using current generation of transcatheter valve devices. The aim was to study the
impact of aortic valve calcification on paravalvular leaks and outcome using the
Edwards SAPIENTM prosthesis.
Methods: 120 consecutive patients (out of 307 TA-AVIs) with preoperative computed
tomography, age 82.6±6.2 years, 75.0% female, were included. Implanted prosthetic
valve sizes were 23 mm (n=31), and 26 mm (n=89), respectively. Mean logistic
EuroSCORE was 30.1±15.5 and mean STS-Score 12.8±7.9. ECG-gated cardiac CT
allowed to quantify the amount of calcification of aortic valve leaflets using a scoring
analogous to the Agatston calcium scoring of coronary arteries (AVCS). Paravalvular
leaks were assessed intraoperatively by echocardiography and angiography.
Results: All valves were implanted successfully. Mean AVCS in patients without
paravalvular leaks (n=66) was 2704±1510, with mild paravalvular leaks (n=31)
3804±2739 (p=0.05) and with moderate paravalvular leaks (n=4) 7387±1044
(p=0.002). There was a significant correlation between AVCS and paravalvular leaks
(r=0.334; p=0.001) indicating, of note, only a limited degree of linear dependence. No
correlation was found to 30-day mortality, postoperative pacemaker-implantation and
stroke-rate (r=0.040, p=0.671; r=0.117, p=0.232 and r=-0.025, p=0.792). Overall 30-
day mortality was 14.2%.
Conclusion: The AVCS identifies patients at risk for a relevant paravalvular leak.
AVCS prior to TA-AVI might serve as an additional tool to reconsider the TAVI
indication and valve size to reduce the risk of paravalvular leaks.
TCT-764
Transcatheter Aortic Valve Replacement: Outcome of Patients with Moderate
or Severe Mitral Regurgitation
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Wood1, Josep Rodes-Cabau2, John G Webb1
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Background: The influence of moderate or severe MR on TAVR outcomes is
unknown.
Methods: This study included 535 consecutive patients undergoing TAVR with a
balloon expandable valve at 2 centers. Patients with moderate or severe MR before
TAVR were compared to patients with none or mild MR. .
Results: A total of 149 patients (28%) presented with concomitant moderate or severe
MR and 386 (72%) had none, trivial or mild MR. Patients with moderate or severe
MR were older (median age 84 vs. 82 years, p = 0.01) and exhibited a higher risk
profile (median STS score 8.2 vs. 7.4 %, p = 0.01). MR improved from moderate or
severe to none or mild at discharge in 79/148 (53%) patients and worsened from none
or mild to moderate or severe in 16/379 (4%). Survival rates for patients with and
without moderate or severe MR at baseline were 85.0% and 93.4% at 30 days, 72.3%
and 79.2% at 1 year, and 53.4% and 51.8% at 3 years, respectively (logrank p = 0.038,
Figure). Moderate or severe MR was an independent risk factor for mortality during
the first 30 days (unadjusted HR 2.32 (95% CI 1.31, 4.11), p < 0.01, adjusted HR 2.25
(1.25, 4.05), p < 0.01), but not after 30 days (unadjusted HR 1.03 (0.57, 1.85), p =
0.92, adjusted HR 1.04 (0.57, 1.90), p = 0.90). At 1 year follow-up, only 4% of the
patients with moderate or severe MR at baseline and 5% of the patients with none or
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mild MR at baseline were in NYHA class III or IV.
Conclusion: Moderate or severe MR in patients undergoing TAVR is associated with
a higher short-term, but not long-term, mortality. MR improves in approximately half
of the patients with moderate or severe MR post TAVR.
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Transcatheter Aortic Valve Implantation – Multicenter Study Evaluating the
Clinical Outcomes of Patients with PARTNER Trial Exclusions
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Background: The randomized PARTNER trial excluded patients with conditions
frequently encountered in clinical practice.
Methods: 242 consecutive high-risk patients (STS >10) undergoing trancatheter aortic
valve implantation (TAVI) were assessed. Patients were divided into a “PARTNER-
exclusions” (PE) group (ejection fraction <20%, severe mitral regurgitation, creatinine
>3.0 mg/dl and/or hemodialysis, significant coronary disease, recent coronary stenting,
cerebrovascular accident within 6-months, annulus diameter <16mm/>24mm, bicuspid
valve, aortic regurgitation >3+, prior valve surgery) and “no PARTNER exclusion”
(NPE) group. The last 4 criteria were also sub-analyzed as “technical exclusions”.
Results: 12-month KM-survival estimates for the PE group were 68.1% vs. 78.2% for
the NPE group (p=0.14). At 3-years this was 40.1% vs. 61.9%, p=0.04. The unadjusted
HR for 3-year mortality for the PE group was 1.61 (95% CL 1.01-2.56), but when
adjusted for baseline differences using a proportional hazard model this was no longer
significant–HR 1.36 (95%CL 0.79-2.35). There were no significant differences in
adjusted survival between the technical groupings either within 30-days (p=0.60) or
1-year (p=0.07). Technical exclusions were not associated with procedural failures and
procedural success rates were excellent (>98%). Ejection fraction <20% trended
(p=0.053) towards lower unadjusted 12-month survival. Patients with severe mitral
regurgitation had similar 12-month survival compared to those without severe
regurgitation.
Conclusion: Patients undergoing TAVI who meet exclusion criteria for the PARTNER
trial represent a high-risk cohort with higher unadjusted long-term mortality, but similar
long-term outcomes when adjusted for baseline risk. Patients with technical exclusion
criteria can still have highly successful procedures. This has important implications
for selection of patients with future “off –label” indications.
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PREDICTORS OF AVB AFTER TAVR WITH THE BOTH EDWARDS AND
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Background: To compare the predictors of high grade atrio-ventricular block (AVB)
after transcatheter aortic valve replacement (TAVR) with the Edwards-Sapien™ THV
(Edwards Lifesciences, Irvine, California) (ESV) and CoreValve ReValving System®
(CoreValve Medtronic Inc, Minneapolis, Minnesota, USA) (CVR)
Methods: We included all consecutive patients undergoing successful TAVR in our
center from November 2007 to March 2011; we excluded 25 patients who had already
a permanent pacemaker and 24 patients whom electrocardiography analysis were not
available.
Results: The study cohort comprised 228 patients: 85 CVR and 143 ESV. Fifty-percent
of the patients were male (63.5% in CVR vs. 46.2% in ESV; p=0.01) and the mean
age was 79±7 years. The patients who underwent TAVR with CVR had a higher
prevalence of poor LVEF (20.0% vs. 10.5%; p=0.04). Baseline electrocardiography
showed a higher prevalence of left bundle brunch block (LBBB) in the CRV then ESV
group (21.2% vs. 8.4%; p=0.006), similar prevalence of right bundle brunch block
(RBBB) (16.5% vs. 13.3%; p=0.50) and wider QRS complex in the CRV then ESV
group (112.6±27.1 ms vs. 105.7±23.4 ms; p=0.04). The incidence of high degree AVB
was higher after CVR (n=15) then ESV (n=10) implantation (17.6% vs. 7.0%; p=0.01).
The multivariable predictors of AVB after TAVR were CVR vs. ESV implantation (OR
2.43, 95%CI 1.00-5.91; p=0.05) and wider baseline QRS (OR 1.02, 95%CI 1.01-1.04;
p<0.001). The univariate predictors of AVB after CVR implantation were the RBBB
(OR 7.87, 95%CI 2.18-28.32; p=0.002) and the wider QRS complex (OR 1.04, 95%CI
1.01-1.06; p<0.001), meanwhile poor LVEF (OR 7.39, 95%CI 1.81-30.21; p=0.005)
and the depth of prosthesis implantation (OR 1.45, 95%CI 1.0-2.06; p=0.03) were the
univariate predictors of AVB after ESV implantation.
Conclusion: The main predictors of AVB after TAVI seem to be the CVR vs. ESV
implantation and a wider QRS complex. RBBB and the wider QRS complex seem to
be predictors in case of CVR implantation, whereas poor LVEF and the depth of
prosthesis implantation seem to be predictors of AVB in the case of ESV implantation.
TCT-767
Gender differences in patients undergoing transcatheter aortic valve
implantation with the Medtronic CoreValve System
Yacine Elhmidi, Nicolo Piazza, Sabine Bleiziffer, Anke Opitz, Hendrik Ruge,
Domenico Mazzitelli, Bernhard Voss, Rüdiger Lange
German Heart Center, Department of cardiovascular Surgery, Munich, Germany
Background: Gender differences in patients undergoing surgical aortic valve
replacement are well documented. Whether gender differences exist in patients
undergoing TAVI is unknown.
Methods: From June 2007 to June 2010, we enrolled 333 consecutive patients who
underwent Medtronic CoreValve implantation. Baseline characteristics and clinical
outcomes were prospectively entered into a dedicated database and differences between
genders were investigated. The primary end-point consisted of a composite outcome
of 1-year mortality.Differences in survival outcomes between genders were estimated
by Kaplan-Meier survival curves.
Results: 152 (46%) were male and 181 (54%) were female. Males had a larger left
ventricular end-diastolic dimensions (51.5 ± 7.7 vs. 45.07 ± 7 mm, p<0.001) and aortic
annulus size (25 ± 1.04 vs. 22.6 ± 1.5 mm, p<0.001) than females. Females were
characterized by higher transaortic mean gradient(49.7 ± 17.7 vs. 45 ± 16 mmHg, p=
0.013). Males were more likely to have coronary artery disease (61.2 vs. 44.7%, p=
0.003) and previous history of coronary artery bypass surgery (28 vs. 6.6%, p<0.001),
more peripheral arterial disease (28 vs. 10.5%, p<0.001), higher baseline creatinine
levels (1.36 ± 0.5 vs. 1.07 ± 0.47 mg/dl, p=<0.001), lower ejections fraction <35%
(23.4 vs. 8.4%, p<0.001), and higher logistic EuroSCORES (21.4 ± 14.4 vs. 17.4 ±
10.7%, p= 0.007). A 26-mm CoreValve was implanted in 62% of females and a 29-
mm CoreValve in 79% in males. Kaplan-Meier survival analyses did not demonstrate
any differences between genders with regards to 30-day or 1-year mortality. Males
were more likely to require post-implant dilatation (28.6 vs. 16.9%, p= 0.011) for
significant paravalvular aortic regurgitation whereas females had a higher occurrence
of post-procedural pericardial effusion > 1cm (4.4 vs. 0%, p= 0.009).
Conclusion: In the current study, males undergoing TAVI had more comorbidities and
higher logistic EuroSCORES than females. There were no significant differences in
30-day or 1-year mortality between genders.
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Transcatheter Aortic Bioprosthesis Embolization: Technical Aspects and Mid-
term Follow-up
Marco Barbanti, Gian Paolo Ussia, Kunal Sarkar, Patrizia Aruta, Valeria
Cammalleri, Marilena Scarabelli, Sebastiano Immè, Simona Gulino, Anna Maria
Pistritto, Massimiliano Mulè, Wanda Deste, Stefano Cannata, Salvatore Scandura,
Corrado Tamburino
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Background: Prosthesis embolization during transcatheter aortic valve implantation
(TAVI) is a rare but important complication, and data on prosthesis performance placed
far from its anatomic position are sparse. We sought to investigate the causes of self-
expanding CoreValve embolization during TAVI and mid-term follow-up of patients
experiencing this acute complication.
Methods: Among 176 consecutive patients undergoing TAVI with CoreValve
prosthesis, 7 (3.9%) experienced acute valve embolization. Accurate analysis of
mechanism of embolization, clinical outcomes and performance of embolized
prosthesis were investigated.
Results: The reasons of valve embolization were classified into three groups: 1)
accidental embolization immediately after valve implantation (N=1; 14.3%) 2)
Embolization during snaring maneuver to reposition a low deployment of the CRS
prosthesis (lower edge >10 mm) below the aortic annulus accompanied with
hemodynamically significant regurgitation (N=4; 57.1%); 3) intentional embolization
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